Daix (France), Long Island City (New York, United States), March 28, 2024 -
Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage
biopharmaceutical company focused on the development of oral small molecule
therapies for the treatment of metabolic dysfunction-associated steatohepatitis
("MASH"), also known as non-alcoholic steatohepatitis ("NASH") and other
diseases with significant unmet medical needs, today announced the nomination of
Andre Turenne to its Board of Directors. Mr. Turenne's appointment will be
submitted to the shareholders for ratification at the next general shareholder
meeting.
Frédéric Cren, Chairman, Chief Executive Officer, and cofounder of Inventiva:
"We are extremely pleased that our Board of Directors has proposed the
appointment of Andre. His deep knowledge of the industry and his experience in
deploying strategic collaborations and executing M&A transactions will be a
strategic experience and know-how for Inventiva, as we enter the final stretch
of our Phase III clinical trial of lanifibranor in NASH. We look forward to
welcoming Andre as the newest member of our Board of Directors."
Mr. Turenne has more than 20 years of global experience in the pharmaceutical
industry. He is currently President and Chief Executive Officer of the Boston-
based biotech Matchpoint Therapeutics, and Advisor to Atlas Venture since 2021.
Prior to joining Matchpoint, Mr. Turenne served as President and Chief Executive
Officer of Voyager Therapeutics. He previously held senior leadership positions
at Sanofi, including Senior Vice President and Global Head of Business
Development & Licensing, responsible for strategic transactions across
therapeutic areas, modalities, and geographies. Mr. Turenne holds a B.A. from
Kalamazoo College and an M.B.A. from the Tuck School of Business at Dartmouth.
Andre Turenne, non-executive director nominee: "I am delighted to have the
opportunity to join the Board of Directors of Inventiva, which is at a pivotal
stage in its clinical program in NASH. I am eager to collaborate with the board
and leadership team to support the company towards fulfilling its mission."
About Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research
and development of oral small molecule therapies for the treatment of patients
with MASH/NASH, and other diseases with significant unmet medical need. The
Company benefits from a strong expertise and experience in the domain of
compounds targeting nuclear receptors, transcription factors and epigenetic
modulation. Inventiva is currently advancing one clinical candidate, has a
pipeline of two preclinical programs and continues to explore other development
opportunities to add to its pipeline.
Inventiva's lead product candidate, lanifibranor, is currently in a pivotal
Phase III clinical trial, NATiV3, for the treatment of adult patients with
MASH/NASH, a common and progressive chronic liver disease for which there are
currently no approved therapies.
Inventiva's pipeline also includes odiparcil, a drug candidate for the treatment
of adult MPS VI patients. As part of Inventiva's decision to focus clinical
efforts on the development of lanifibranor, it suspended its clinical efforts
relating to odiparcil and is reviewing available options with respect to its
potential further development. Inventiva is also in the process of selecting a
candidate for its Hippo signaling pathway program.
The Company has a scientific team of approximately 90 people with deep expertise
in the fields of biology, medicinal and computational chemistry,
pharmacokinetics and pharmacology, and clinical development. It owns an
extensive library of approximately 240,000 pharmacologically relevant molecules,
approximately 60% of which are proprietary, as well as a wholly-owned research
and development facility.
Inventiva is a public company listed on compartment B of the regulated market of
Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market
in the United States (ticker: IVA). www.inventivapharma.com
(http://www.inventivapharma.com/)
Contacts
Brunswick Group
Tristan Roquet Montegon Westwicke, an ICR
Inventiva / Company
Aude Lepreux / Patricia L. Bank
Pascaline Clerc Julia Cailleteau Investor relations
EVP, Strategy and Media relations patti.bank@westwicke.c
Corporate Affairs inventiva@brunswickgrou om
media@inventivaphar p.com (mailto:patti.bank@wes
ma.com (mailto:inventiva@bruns twicke.com)
(mailto:media@inven wickgroup.com)
tivapharma.com) +1
+1 202 499 8937 +33 1 53 96 83 83 415 513-1284
Important Notice
This press release contains "forward-looking statements" within the meaning of
the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. All statements, other than statements of historical facts, included in
this press release are forward-looking statements.
These statements include, but are not limited to, forecasts and estimates with
respect to the results of Inventiva's annual general meeting of shareholders,
including with respect to the appointment of Mr. Turenne, Inventiva's clinical
trials, including the ongoing NATiV3 Phase III clinical trial with lanifibranor
in MASH/NASH, its pipeline and preclinical and clinical development plans, the
potential development of and regulatory pathway for odiparcil, and future
activities, expectations, plans, growth and prospects of Inventiva. Certain of
these statements, forecasts and estimates can be recognized by the use of words
such as, without limitation, "believes", "anticipates", "expects", "intends",
"plans", "seeks", "estimates", "may", "will", "would", "could", "might",
"should", "designed", "hopefully", "target", "potential", "opportunity",
"possible", "aim", and "continue" and similar expressions. Such statements are
not historical facts but rather are statements of future expectations and other
forward-looking statements that are based on management's beliefs. These
statements reflect such views and assumptions prevailing as of the date of the
statements and involve known and unknown risks and uncertainties that could
cause future results, performance, or future events to differ materially from
those expressed or implied in such statements. Actual events are difficult to
predict and may depend upon factors that are beyond Inventiva's control. There
can be no guarantees with respect to pipeline product candidates that the
clinical trial results will be available on their anticipated timeline, that
future clinical trials will be initiated as anticipated, that product candidates
will receive the necessary regulatory approvals, or that any of the anticipated
milestones by Inventiva or its partners will be reached on their expected
timeline, or at all. Future results may turn out to be materially different from
the anticipated future results, performance or achievements expressed or implied
by such statements, forecasts and estimates, due to a number of factors,
including that Inventiva cannot provide assurance on the impacts of the SUSAR on
enrolment or the ultimate impact on the results or timing of the NATiV3 trial or
regulatory matters with respect thereto, that Inventiva is a clinical-stage
company with no approved products and no historical product revenues, Inventiva
has incurred significant losses since inception, Inventiva has a limited
operating history and has never generated any revenue from product sales,
Inventiva will require additional capital to finance its operations, in the
absence of which, Inventiva may be required to significantly curtail, delay or
discontinue one or more of its research or development programs or be unable to
expand its operations or otherwise capitalize on its business opportunities and
may be unable to continue as a going concern, Inventiva's future success is
dependent on the successful clinical development, regulatory approval and
subsequent commercialization of current and any future product candidates,
preclinical studies or earlier clinical trials are not necessarily predictive of
future results and the results of Inventiva's and its partners' clinical trials
may not support Inventiva's and its partners' product candidate claims,
Inventiva's expectations with respect to its clinical trials may prove to be
wrong and regulatory authorities may require holds and/or amendments to
Inventiva's clinical trials, Inventiva's expectations with respect to the
clinical development plan for lanifibranor for the treatment of MASH/NASH may
not be realized and may not support the approval of a New Drug Application,
Inventiva and its partners may encounter substantial delays beyond expectations
in their clinical trials or fail to demonstrate safety and efficacy to the
satisfaction of applicable regulatory authorities, the ability of Inventiva and
its partners to recruit and retain patients in clinical studies, enrollment and
retention of patients in clinical trials is an expensive and time-consuming
process and could be made more difficult or rendered impossible by multiple
factors outside Inventiva's and its partners' control, Inventiva's product
candidates may cause adverse drug reactions or have other properties that could
delay or prevent their regulatory approval, or limit their commercial potential,
Inventiva faces substantial competition and Inventiva's and its partners'
business, and preclinical studies and clinical development programs and
timelines, its financial condition and results of operations could be materially
and adversely affected by geopolitical events, such as the conflict between
Russia and Ukraine and related sanctions, impacts and potential impacts on the
initiation, enrollment and completion of Inventiva's and its partners' clinical
trials on anticipated timelines and the state of war between Israel and Hamas
and the related risk of a larger conflict, health epidemics, and macroeconomic
conditions, including global inflation, rising interest rates, uncertain
financial markets and disruptions in banking systems, and the vote of
Inventiva's shareholders. Given these risks and uncertainties, no
representations are made as to the accuracy or fairness of such forward-looking
statements, forecasts, and estimates. Furthermore, forward-looking statements,
forecasts and estimates only speak as of the date of this press release. Readers
are cautioned not to place undue reliance on any of these forward-looking
statements.
Please refer to the Universal Registration Document for the year ended December
31, 2022 filed with the Autorité des Marchés Financiers on March 30, 2023 as
amended on August 31, 2023, the Annual Report on Form 20-F for the year ended
December 31, 2022 filed with the Securities and Exchange Commission (the "SEC")
on March 30, 2023, and the Half-Year Report for the six months ended June
30, 2023 on Form 6-K filed with the SEC on October 3, 2023, for other risks and
uncertainties affecting Inventiva, including those described under the caption
"Risk Factors", and in our future filings with the SEC, including our Annual
Report on Form 20-F for the year ended December 31, 2023 to be filed with the
SEC. Other risks and uncertainties of which Inventiva is not currently aware may
also affect its forward-looking statements and may cause actual results and the
timing of events to differ materially from those anticipated. All information in
this press release is as of the date of the release. Except as required by law,
Inventiva has no intention and is under no obligation to update or review the
forward-looking statements referred to above. Consequently, Inventiva accepts no
liability for any consequences arising from the use of any of the above
statements.
Â